Cordlife (SGX:P8A) unveiled an enhanced processing and storage facility as the company looks to resume cord blood banking activities in Singapore, according to a filing with the Singapore Exchange on Tuesday.
In 2023, Cordlife was ordered to stop collecting, testing, processing, and storing any new cord blood and human tissue, or to conduct new tests after the company was found to have damaged cord blood units due to mishandling.
But last August, the Ministry of Health issued Cordlife a third notice allowing it to restart cord blood banking services under new restrictions after meeting the agency's requirements.
Cordlife said the new facility is equipped with an advanced laboratory monitoring system that will track cryogenic storage tanks and other critical equipment to ensure surveillance.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。